Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

The Importance of Non-essential Amino Acids for Maintaining Skeletal Muscle Protein Synthesis Rates in Healthy Young Men

NCT06687343 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2024-11-14
Last updated
2024-12-24

Condition(s) studied

Healthy Males

Investigational drug(s) / intervention(s)

EAA SupplementNEAA SupplementMaltodextrin Supplement

EAA Supplement: Dissolved in water and ingested 4 times a day

NEAA Supplement: Dissolved in water and ingested 4 times a day

Maltodextrin Supplement: Dissolved in water and ingested 4 times a day

Study summary

Background: Protein intake is important for maintaining skeletal muscle mass. These proteins consist of a collection of small building blocks which are called amino acids. There are two types of amino acids that are needed to build muscle: essential amino acids (EAA) and non-essential amino acids (NEAA). EAAs cannot be made in the body and must be consumed through foods, while NEAAs can be made within the body. However, if NEAA are not consumed through foods, the process of making NEAA in the body costs the body energy. It is still unknown what the impact of a diet containing too few non-essential amino acids is for muscle building and the body's energy metabolism.

Objective: To determine if a diet lacking NEAA, with or without being replaced by additional EAA, influences muscle protein building and whole-body metabolism.

Study design: Randomized, parallel design, double-blind, 10-day dietary intervention study.

Study population: 45 healthy (BMI 22-30 kg/m2) young males (age: 18-35 y inclusive).

Hypothesis: It is hypothesized that a diet lacking NEAA, with or without being replaced by additional EAA, decreases muscle protein building in humans.

Eligibility

Sex
MALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male * Age between 18 and 35 y inclusive * BMI between 22 and 30 kg/m2 * Non-smoker * Having given informed consent Exclusion Criteria: * Participating in a structured (progressive) exercise program * Smoker * Diagnosed GI tract disorders or diseases * Diagnosed musculoskeletal disorders * Diagnosed metabolic disorders (e.g. diabetes) * Cardiovascular disease * Hypertension (blood pressure above 140/90 mmHg) * Donated blood 3 months prior to test day * Use of any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories). * Chronic use of gastric acid suppressing medication * Chronic use of anti-coagulants * Any intolerance to foods included in the standardized diet intervention * Any implants that would be a contra-indication for performing an MRI scan

Primary outcome measure(s)

  • Integrated skeletal muscle protein fractional synthesis rates — 10 days
    Calculated by the change in deuterium labelled alanine in skeletal muscle protein

Trial sites (1)

FacilityCityRegionStatus
Maastricht University Medical Center Maastricht Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06687343 on ClinicalTrials.gov ↗ ← All trials in the Netherlands